Heineken N.V. announces second tranche of its €1.5 billion share buyback programme Heineken N.V. announces second tranche of its €1.5 billion share buyback programme Amsterdam, 12 February 2026 – Heineken N.V. (HEINEKEN) (EURONEXT:HEIA; OTCQX: HEINY) announces the start of the second €750 million tranche of its €1.5 billion two-year share buyback programme as communicated on 12 February 2025. Heineken Holding N.V. (Heineken Holding), HEINEKEN's majority shareholder, will participate pro rata to its shareholding in HEINEKEN's share buyback programme on a daily basis, pursuant to an agreem...
ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...
Heineken's FY25 top line and operating profit figures were slightly better than our forecasts with operating profit in absolute terms in line with consensus. Heineken guides again for sizeable savings efforts in FY26 with operating profit growth guidance calling for a 2-6% range (vs our and consensus forecasts of c. 5%). We still appreciate Heineken for the sizeable self-help initiatives which should support organic earnings growth in the coming years, but acknowledge that the bumpier volume evo...
HEINEKEN N.V. REPORTS 2025 FULL YEAR RESULTS Amsterdam, 11 February 2026 HEINEKEN N.V. REPORTS 2025 FULL YEAR RESULTS Well-balanced performance in challenging market conditions IFRS Measures BEIA Measures(in € million) Total growth (in € million) Organic growthRevenue 34,257 -4.7% Revenue (beia) 34,395 0.2%Net revenue 28,753 -3.6% Net revenue (beia) 28,890 1.6%Operating profit 3,406 -3.2% Operating profit (beia) 4,385 4.4%Operating profit margin 11.8% 5 bps Operating profit (beia) margin 15.2% 41 bpsNet profit 1,885 92.7% Net profit (beia) 2,662 4.9%Diluted EPS 3....
Heineken is due to report its full year results on 11 February. Based on information disclosed in its full year aide memoire, we have adjusted our forecasts to account for weaker than previously expected volumes in Western Europe and Americas. We have also increased our 12-month target price from €64.62 to €76.13 and maintain our HOLD recommendation.
Xior reported solid operational FY25 results. We remain very supportive of the excellent organic trends: LFL rental growth of +5.4% over FY25, which is expected to reach a minimum of +4% over 2026-27F, still outperforming the broader real estate space. The 4% EPS growth guidance for 2026 and 2027 is strong and we think this is a realistic expectation. LTV is at 49.9% and this limits growth options. Over the next two years the group focus will be on rental growth, operational leverage and the exe...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen
UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...
Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.